https://medicine.ouhsc.edu/Academic-Departments Parent Page: Academic Departments id: 22035 Active Page: Research Fundingid:22037

Research Funding

ACTIVE Research Support

OSCTR Pilot Grant, NIH IDeA Program, Queimado (PI)
04/03/2020-06/30/2021
National Institutes of Health (NIH)
A new molecular tool to predict cervical cancer progression

The main objective of this study is to gather preliminary data on the levels of DNA damage in cervical dysplasia samples and on their value as a tool to predict cervical cancer risk.

OTRC Pilot Grant, Tackett (PI) Queimado (Co-I)
01/01/2020-12/31/2020
Oklahoma Tobacco Research Center (OTRC)
The Acute Toxicological and Respiratory Profile of IQOS: A Preliminary Switch Trial

Specific aims of this study are: (1) to assess the effect of provision of 'I-Quit-Original-Smoking' (IQOS) vs. usual brand cigarette control (UBC) on abuse liability, number of cigarettes smoked, product evaluation, and perceived nicotine dependence; (2) to evaluate changes in biomarkers of exposure and DNA damage among participants assigned to IQOS or UBC; and (3) to compare acute changes in pulmonary functioning and respiratory health between IQOS and UBC via ecological momentary assessment (EMA) and repeated laboratory sessions.

PHF Bridge Grant, Queimado (PI)
10/01/2019-09/30/2020
Presbyterian Health Foundation (PHF) 
Biological impact of exclusive and dual e-cigarette use on oral cancer risk
The main objective of this study is to obtain preliminary data on how electronic cigarette use changes gene expression, and how those changes might contribute to human cancer.
 
 
1R01 CA194158-01, NIH/NCI, Wagener (PI) Queimado (Co-I)
11/01/2016-10/31/2021
National Institutes of Health (NIH)/National Cancer Institute (NCI)        
Examination of First and Second Generation E-cigarettes                                    
Specific aims of this project are: (1) to assess the effect of provision of G1 vs. G2 on product switching/substitution, abuse liability, number of cigarettes smoked, and perceived nicotine dependence; (2) to evaluate changes in biomarkers of harmful tobacco constituent exposure among participants assigned to G1, G2, and UBC; and (3) to evaluate changes in biomarkers of toxicant effect among participants assigned to G1, G2, and UBC.
 
 
1 R01 CA196200-01A1, NIH/NCI, Benbrook (PI) Queimado (Co-I)          
07/01/2015-06/30/2020
National Institutes of Health (NIH)/National Cancer Institute (NCI)
Ovarian Cancer Chemoprevention
The goals of this project are: (1) to conduct a Phase 0 Clinical Trial of SHetA2 to determine the minimal dose needed to achieve micromolar blood and Fallopian tube tissue drug levels; (2) to test the chemoprevention activity of SHetA2 in a mouse model of Fallopian tube tumorigenesis; and (3) to study the mortalin interactome in the development of SHetA2 sensitivity during Fallopian tube tumorigenesis and as pharmacodynamics candidates for future chemoprevention clinical trials.
 
 
Clinical Trial, Gunderson (PI) Queimado (Translational Studies, PI)                                                
Stephenson Cancer Center (Sponsor) & Clovis Oncology (Funding Collaborator)
A Phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium

The primary objective of this study is to determine whether the combination of rucaparib and bevacizumab will produce synergistic anti-cancer effect and increase progression-free survival (PFS) in patients with the carcinoma of the cervix or endometrium. The translational objective of this study is to determine whether the level of DNA damage in patient tumor biopsies is associated with response, PFS, and/or overall survival. 

092-016-0002, OTRC Expansion Grant, Businelle (PI) Queimado (TSET Scholar)                
07/01/2015-06/30/2020      
Oklahoma Tobacco Research Center (OTRC) Tobacco Settlement Endowment Trust (TSET)       
The purpose of this project is to establish the TSET Cancer Research Program to advance translational, clinical and population-based cancer research and serve to enhance efforts to prevent and combat cancer.

Presbyterian Health Foundation Chair in Otorhinolaryngology  
November 2002-present                                                                                         
The purpose of this endowment is to foster head and neck cancer research by developing research resources within the Otorhinolaryngology department and providing research training for Otorhinolaryngology residents and fellows.

COMPLETED Research Support (past 2 years)

1 R33 CA202898-01, NIH/NCI, Queimado (PI)                              
04/08/2016-03/31/2020
National Institute of Health (NIH)/National Cancer Institute (NCI)        
A novel molecular assay for early detection and assessment of cancer risk                          
The goals of this project are: (1) to advance the development and standardization of q-PADDA for high-throughput DNA damage quantification in human samples; (2) to validate q-PADDA for DNA damage quantification and cancer risk assessment in populations with relevant mutagen exposure; and (3) to validate q-PADDA as a screening tool for the early detection of head and neck cancer.
 
PHF Bridge Grant, Queimado (PI)
09/01/2018-08/31/2019
Presbyterian Health Foundation (PHF)

The role of electronic cigarettes in oral mucosa genotoxicity and oncogenesis                   
The main objective of this study is to obtain preliminary data on how electronic cigarette use changes gene expression, and how those changes might contribute to human cancer.

HR16-007, OCAST, Queimado (PI)
09/01/2016-08/31/2019
Oklahoma Center for the Advancement of Science and Technology (OCAST)                            
Studying the effects of tobacco smoking on oral stem cells  
The goals of this project are: (1) to determine the effects of active and passive tobacco smoke on oral SC self-renewal and differentiation; (2) to characterize the impact of tobacco-smoke on the expression of Wnt genes; and (3) to establish whether WNT1 prevents DNA damage induced cell death in oral SCs and is a potential therapeutic target for oral squamous cell carcinoma.
     

PHF Bridge Grant, Metcalf (PI) Queimado (Co-I)
09/30/2017-09/29/2018
Presbyterian Health Foundation (PHF)
Immunosuppressive Effects of E-cigarettes 

Inventions/Patent

U.S. Patent Application 13/565,604: A Novel DNA Damage Detection Assay